ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Monday, November 6, 2017

9:00AM-11:00AM
Abstract Number: 1084
Emdhaq: (electronic multidimensional health assessment questionnaire) to Record and Document eRAPID3 (electronic routine assessment of patient index data3) and eFAST3 (electronic fibromyalgia assessment screening tool3) in Routine Rheumatology Care
Measures and Measurement of Healthcare Quality Poster I
9:00AM-11:00AM
Abstract Number: 1608
Entheseal Involvement in Systemic Lupus Erythematosus: An Ultrasound Study
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities
9:00AM-11:00AM
Abstract Number: 1168
Eosinophilic Fasciitis:  Baseline Retrospective Evaluation of Clinical Characteristics and Prognosis in a Cohort of 83 Patients
Miscellaneous Rheumatic and Inflammatory Diseases Poster I
9:00AM-11:00AM
Abstract Number: 982
Epidemiology and Mortality in Systemic Sclerosis in South Korea: A Nationwide Population-Based Study
Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1379
Epithelial Neutrophil-Activating Peptide 78/C-X-C Motif Chemokine 5 in the Insulin Resistance of Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures
9:00AM-11:00AM
Abstract Number: 1233
Establishing and Maintaining a Volunteer Charity Rheumatology Clinic: One Clinic’s Experience
Patient Outcomes, Preferences, and Attitudes Poster II
9:00AM-11:00AM
Abstract Number: 1217
Evaluation of Post Fracture Management in Males at a Veterans Affairs Health System
Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 1366
Evaluation of Synovial Fluid 14-3-3η Protein As a Marker of Joint Damage in Rheumatoid Arthritis Patients
Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures
9:00AM-11:00AM
Abstract Number: 1545
Evaluation of the Adherence to Recommendations for Tnfα Blockers Use and Its Impact over 5 Years of Follow-up in Early Axial Spondyloarthritis. Data from the DESIR Cohort
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II
9:00AM-11:00AM
Abstract Number: 1441
Evaluation of Ultrasound-Detecting Efficacy of Abatacept By Profiling Multiple Serum Cytokines, Chemokines and Bone-Related Biomarkers in Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort Study
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports
9:00AM-11:00AM
Abstract Number: 1248
Evaluation of Validated Patient Reported Outcome Measures to Assess Sensitivity to Change in Patients with Systemic Sclerosis and Gastroesophageal Reflux Disease —a Scleroderma Clinical Trials Consortium Collaborative Project
Patient Outcomes, Preferences, and Attitudes Poster II
9:00AM-11:00AM
Abstract Number: 1056
Evolution of Health Care Consumption in the Knee and Hip Osteoarthritis Long Term Assessment Cohort, a French Population Based Cohort of Symptomatic Knee and/or Hip OA Patients
Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 1568
Existence of IL-6 and IL-17 Mediated Inflammation Amplifier Loop in Reactive Arthritis
Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster II
9:00AM-11:00AM
Abstract Number: 1197
Exploring Determinants Predicting Response to Intra-Articular Hyaluronic Acid Treatment in Symptomatic Knee Osteoarthritis
Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions
9:00AM-11:00AM
Abstract Number: 1285
Extracutaneous Involvement Is Common in Juvenile Localized Scleroderma and Associated with a Higher Level of Perceived Disease Impact
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis
  • «Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology